Abstract: The present disclosure relates to a crystalline form of (((((E)-1-((8S,9S,10R, 13S,14S,17S)-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethylidene)amino)oxy)methyl dihydrogen phosphate), and pharmaceutically acceptable salts thereof, which may be useful in methods of treatment of the human or animal body. The present disclosure also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them and to their use in the treatment of disorders, such as managing inflammation (e.g., inflammation resulting from traumatic brain injury or stroke).

Abstract: According to one embodiment, a system comprises a processor-based device and a startup application that is operable to determine one of a plurality of different shells presented by the processor-based device based on a user's identity information.

Abstract: Disclosed are systems, devices and methods for deployment in digital set-top boxes and associated networks to enable t-commerce and other transactions responsive to events generated by peripheral devices.

Abstract: Disclosed are systems, devices and methods for deployment in digital set-top boxes and associated networks to enable t-commerce and other transactions responsive to events generated by peripheral devices.

Abstract: Disclosed are systems, devices and methods for deployment in digital networks to enable t-commerce and other transactions responsive to events generated by peripheral devices.